BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis
Corporation ("IsoPlexis"), a leader in functional single-cell
proteomics, today announced the closing of its initial public
offering of 8,333,000 shares of common stock at a public offering
price of $15.00 per share. The gross
proceeds from the offering, before deducting underwriting discounts
and commissions and other offering expenses payable by IsoPlexis,
were $125.0 million. IsoPlexis'
common stock began trading on The Nasdaq Global Select Market on
October 8, 2021, under the ticker
symbol "ISO." All shares in the offering were offered by
IsoPlexis.
Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting
as lead book-running managers for the offering.
A registration statement on Form S-1 relating to the shares
being sold in this offering was declared effective by the
Securities and Exchange Commission on October 7, 2021. The offering is being made only
by means of a prospectus, copies of which may be obtained, when
available, from: Morgan Stanley & Co. LLC, Attn: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866)
718-1649 or by email at prospectus@morganstanley.com; Cowen
and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY,11717,
Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets,
55 East 52nd Street, 36th Floor, New
York, NY 10055, or by telephone at 888-474-0200, or by email
at ecm.prospectus@evercore.com; or SVB Leerink LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at
(800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
Copies of the final prospectus related to the offering will be
available at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About IsoPlexis
IsoPlexis is a life science technology company building
solutions to accelerate the development of curative medicines and
personalized therapeutics. Our award-winning single-cell proteomics
systems reveal unique biological activity in small subsets of
cells, allowing researchers to connect more directly to in
vivo biology and develop more precise and personalized
therapies. Our integrated systems, named top innovation or design
by the Scientist Magazine, Fierce, BIG Innovation, Red Dot &
multiple others, are used globally to advance the field of
single-cell biology into new 'omic possibilities, as our customers
generate solutions to overcome the challenges of complex diseases
and therapeutics. Our products have been adopted by
researchers around the world, including the top 15 global
pharmaceutical companies by revenue and by nearly half of
comprehensive cancer centers in the U.S.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-announces-closing-of-public-offering-301398547.html
SOURCE IsoPlexis